By Steve Usdin
Contributing Editor

SILVER SPRING, Md. - Even as biotech companies are moving into late-stage human trials of drugs to treat systemic lupus erythematosus, the FDA is still looking for a coherent way to assess the efficacy of therapies for the highly complex autoimmune disorder, which follows dramatically heterogeneous paths in different individuals, involves multiple organs, and presents varying states of activity.